Enlie Pharmaceutical JSC

Enlie Pharmaceutical JSC EBIT Margin

The EBIT Margin (Operating Margin) of Enlie Pharmaceutical JSC (BCP.VN) as of Oct 23, 2026 is 2.50 %. In the previous year, EBIT Margin (Operating Margin) was -2.67 % — a change of -193.50% (higher).

EBIT Margin

2.50 %

YoY

-193.50%

Last updated:

EBIT Margin (Operating Margin) of Enlie Pharmaceutical JSC is 2024 2.50 % . EBIT Margin (Operating Margin) of Enlie Pharmaceutical JSC was 2023 -2.67 % . It decreases by -193.50% higher compared to the previous year.

For Enlie Pharmaceutical JSC, the operating (EBIT) margin of 2.5% is up versus -22.8% a few years ago.

The Enlie Pharmaceutical JSC EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2017
11.24 VND
Jan 1, 2018
17.46 VND
Jan 1, 2019
-6.20 VND
Jan 1, 2020
-22.83 VND
Jan 1, 2021
-6.25 VND
Jan 1, 2022
1.51 VND
Jan 1, 2023
-2.67 VND
Jan 1, 2024
2.50 VND
The Enlie Pharmaceutical JSC EBIT Margin history
YEAREBIT MarginYoY
2.50 %-193.50%
-2.67 %-277.47%
1.51 %-124.08%
-6.25 %-72.62%
-22.83 %+268.32%
-6.20 %-135.51%
17.46 %+55.31%
11.24 %+31.09%
8.57 %+33.43%
6.43 %-47.85%
12.32 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Enlie Pharmaceutical JSC Stock analysis

What does Enlie Pharmaceutical JSC do? Enlie Pharmaceutical JSC generates revenue primarily through the manufacture and commerce of pharmaceutical preparations, medical equipment, and health supplements. The company leverages its core expertise in these healthcare categories to serve the market, establishing its primary income streams around the production and sale of these essential health products. In addition to its pharmaceutical operations, the firm has diversified its business model by expanding into the real estate industry. This segment involves the development of various commercial and residential infrastructures which are then made available for lease, providing an additional layer of financial activity beyond its core healthcare focus. Enlie Pharmaceutical JSC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enlie Pharmaceutical JSC stock

EBIT Margin (Operating Margin) of Enlie Pharmaceutical JSC is 2.50 % in 2024.

EBIT Margin (Operating Margin) of Enlie Pharmaceutical JSC changed from -2.67 % to 2.50 %, representing a -193.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Enlie Pharmaceutical JSC since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Enlie Pharmaceutical JSC with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Enlie Pharmaceutical JSC

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Enlie Pharmaceutical JSC